Format

Send to

Choose Destination
Cancer Biol Ther. 2016 Apr 2;17(4):407-13. doi: 10.1080/15384047.2016.1156256. Epub 2016 Mar 8.

PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.

Ji M1,2, Liu Y3, Li Q4, Li X1,2,5, Ning Z6, Zhao W1, Shi H1, Jiang J2,5, Wu C1,2,5.

Author information

1
a Department of Oncology , The Third Affiliated Hospital of Soochow University , Changzhou , China.
2
b Jiangsu Engineering Research Center for Tumor Immunotherapy , Changzhou , China.
3
c Department of Hematology , The Third Affiliated Hospital of Soochow University , Changzhou , China.
4
d Department of Pathology , The Third Affiliated Hospital of Soochow University , Changzhou , China.
5
e Department of Biological Treatment , The Third Affiliated Hospital of Soochow University , Changzhou , China.
6
f Department of Radiation Oncology , The Third Affiliated Hospital of Soochow University , Changzhou , China.

Abstract

This study was aimed to detect the correlation among EGFR/KRAS status and PD-1/PD-L1 expression in non-small-cell lung cancer (NSCLC) patients. PD-1 and PD-L1 expressions were detected by immunohistochemistry in 100 surgically resected lung adenocarcinoma tissues and were statistically correlated with clinicopathological characteristics including EGFR and KRAS statuses. Besides, the overall survival (OS) times were analyzed. There was a statistical significances between PD-1 expression in tumor and KRAS status (P = 0.043), with a higher mutation rate in with lower PD-1 expression patients. There was a statistical significance between PD-L1 expression in tumor and EGFR status (P = 0.012), with a higher mutation rate in patients with lower PD-L1 expression. The OS of patients with EGFR mutation was significantly longer than those without EGFR mutation. The OS of patients with lower PD-L1 in tumor was significantly longer than those with higher PD-L1 expression. We found negative associations between PD-L1 expression in tumor and mutated EGFR status, as well as between PD-1 expression in tumor and mutated KRAS status.

KEYWORDS:

EGFR; KRAS; PD-1; PD-L1; non-small-cell lung cancer

PMID:
26954523
PMCID:
PMC4910919
DOI:
10.1080/15384047.2016.1156256
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center